使用瑞巴派特溶液作为粘膜下注射材料预防内镜粘膜下剥离术后食管狭窄：动物研究
Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study.
摘要(中文译文)
开发一种安全、经济有效且简便的方法来预防食管内镜黏膜下剥离术（ESD）后狭窄是令人期望的。我们探索了一种新型瑞巴派特溶液——一种抗溃疡药物——作为黏膜下注射材料用于预防ESD后食管狭窄。在15头猪中，使用2%瑞巴派特溶液或生理盐水（对照）作为黏膜下注射材料，在中段胸食管近端和远端分别进行两处半环周ESD。分别在术后第7天、第14天和第21天各处死5头猪。每周进行随访内镜检查直至处死。评估ESD相关结局、狭窄程度及组织学特征。两组ESD相关结局相似，所有ESD后溃疡均在术后第14天前完成上皮化。瑞巴派特组和对照组在术后第14天和第21天的平均黏膜收缩率分别为19.1 ± 7.2% vs. 21.0 ± 6.4%（P = 0.40）和13.3 ± 6.8% vs. 20.8 ± 6.1%（P = 0.08）。瑞巴派特组在术后第21天达到峰值且收缩程度较轻，而对照组似乎趋于平台期。组织学上，瑞巴派特组和对照组在第14天和第21天的平均纤维化厚度分别为807.0 ± 238.9 µm vs. 972.8 ± 395.1 µm（P = 0.40）和782.8 ± 281.5 µm vs. 1087.0 ± 476.1 µm（P = 0.13）。瑞巴派特溶液在预防ESD后狭窄方面未显示出统计学显著的益处。然而，鉴于本研究样本量较小，需要进一步研究以阐明其潜在作用。
Abstract
It is desirable to develop a safe, cost-effective, and easy approach to prevent strictures after esophageal endoscopic submucosal dissection (ESD). We explored use of a novel rebamipide solution, an anti-ulcer drug, as a submucosal injection material for preventing esophageal stricture after ESD. In 15 swine, two half-circumferential ESDs were performed at the proximal and distal ends of the middle thoracic esophagus using 2% rebamipide solution or saline (control) as submucosal injection material. Five swine were sacrificed on postoperative days (PODs) 7, 14, and 21, respectively. Follow-up endoscopy was performed weekly until sacrifice. ESD-related outcomes, degree of stricture, and histological characteristics were evaluated. ESD-related outcomes were similar in both groups, with all post-ESD ulcers epithelialized by POD 14. Mean mucosal constriction rate in the rebamipide and control groups on PODs 14 and 21 were 19.1 ± 7.2% vs. 21.0 ± 6.4% ( = 0.40) and 13.3 ± 6.8% vs. 20.8 ± 6.1% ( = 0.08), respectively. The rebamipide group peaked and showed milder constriction by POD 21, whereas the control group seemed to plateau. Histologically, mean fibrosis thickness in the rebamipide and control groups on days 14 and 21 were 807.0 ± 238.9 µm vs. 972.8 ± 395.1 µm ( = 0.40) and 782.8 ± 281.5 µm vs. 1087.0 ± 476.1 µm ( = 0.13), respectively. The rebamipide solution showed no statistically significant benefit in preventing post-ESD stricture. However, given the small sample size of this study, further studies are needed to clarify its potential role.
如何引用
AMA
Yuichiro Hirai, Ai Fujimoto, Motoki Sasaki, Masayuki Shimoda, Naohisa Yahagi. Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study.. Endoscopy international open. 2026; doi:10.1055/a-2820-3721.
APA
Yuichiro Hirai, Ai Fujimoto, Motoki Sasaki, Masayuki Shimoda, Naohisa Yahagi (2026). Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study.. Endoscopy international open. https://doi.org/10.1055/a-2820-3721
GB/T 7714
Yuichiro Hirai, Ai Fujimoto, Motoki Sasaki, Masayuki Shimoda, Naohisa Yahagi. Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study.[J]. Endoscopy international open, 2026 doi:10.1055/a-2820-3721.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出